EDGAR Filing Documents for 0001640334-21-001097

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:

SEC Accession No. 0001640334-21-001097

Filing Date

2021-05-06

Accepted

2021-05-06 12:36:29

Documents

Period of Report

2021-04-30

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 6-K	nymox_6k.htm	6-K	22432
2	EX-4.1	nymox_ex41.htm	EX-4.1	89601
3	EX-4.2	nymox_ex42.htm	EX-4.2	92673
4	EX-10.1	nymox_ex101.htm	EX-10.1	44852
5	EX-10.2	nymox_ex102.htm	EX-10.2	225798
6	EX-10.3	nymox_ex103.htm	EX-10.3	125890
7	EX-99.1	nymox_ex991.htm	EX-99.1	9692
8		nymox_ex991img4.jpg	GRAPHIC	4410
9		nymox_ex991img5.jpg	GRAPHIC	2785
10		nymox_ex991img3.gif	GRAPHIC	5501
	Complete submission text file	0001640334-21-001097.txt		629861

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 21896774
SIC: 2835 In Vitro & In Vivo Diagnostic Substances